2-(2,6-Dichlorbenzamid)-2-imidazolin | 36145-64-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2,6-Dichlorbenzamid)-2-imidazolin
• 英文别名: 2-(2,6-Dichlorbenzamido)-2-imidazolin；2,6-dichloro-N-(4,5-dihydro-1H-imidazol-2-yl)-benzamide；2,6-dichloro-N-(4,5-dihydro-1H-imidazol-2-yl)benzamide
• CAS: 36145-64-9
• 化学式: C₁₀H₉Cl₂N₃O
• 分子量: 258.107
• InChiKey: FIEAGGWJKSOGDQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  53.5
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• METHOD OF TREATING A PATHOLOGICAL SYNDROME
  申请人：Epshtein Oleg Iliich

  公开号：US20160229914A1

  公开（公告）日：2016-08-11

  A method of treating disorder or condition that relates to intracellular signal transmission of a neurotransmitter, comprising administration of an homeopathically potentized form of antibodies to an antigen, which antigen is a molecule capable of effecting the intracellular signal transmission of a neuroreceptor, in particular dopamine or serotonin.

  一种治疗与神经递质的细胞内信号传递相关的疾病或症状的方法，包括给予一种高度稀释的抗原抗体制剂，该抗原是一种能够影响神经受体的细胞内信号传递的分子，特别是多巴胺或血清素。
• CURING METHOD FOR PATHOLOGIC SYNDROME AND A MEDICINAL PREPARATION
  申请人：Epshtein, Oleg Iliich

  公开号：EP1295606A1

  公开（公告）日：2003-03-26

  A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too.

  一种治疗病理综合征的方法，包括给药超低剂量抗原抗体的活化形式，其中所述活化形式是通过反复连续稀释结合外部影响获得的，抗原是对该特定病理综合征的形成机制有影响的物质或药剂。 治疗病理综合征的药剂包含超低剂量的抗原单克隆抗体、多克隆抗体或天然抗体的活化形式，其中所述活化形式是通过反复连续稀释和外部处理的方法制备的，主要基于顺势疗法技术，所述抗原是作为病理综合征的直接原因或参与调节其形成机制的物质或药物。在这种情况下，针对外源性或内源性抗原、自体抗原、胎儿抗原的超低剂量抗体活化形式就会产生。
• Curing method for pathologic syndrome and medicinal preparation
  申请人：——

  公开号：US20030099636A1

  公开（公告）日：2003-05-29

  A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too.

  一种治疗病理综合征的方法，包括给药超低剂量抗原抗体的活化形式，其中所述活化形式是通过反复连续稀释结合外部影响获得的，抗原是对该特定病理综合征的形成机制有影响的物质或药剂。 治疗病理综合征的药剂包含超低剂量的抗原单克隆抗体、多克隆抗体或天然抗体的活化形式，其中所述活化形式是通过反复连续稀释和外部处理的方法制备的，主要基于顺势疗法技术，所述抗原是作为病理综合征的直接原因或参与调节其形成机制的物质或药物。在这种情况下，针对外源性或内源性抗原、自体抗原、胎儿抗原的超低剂量抗体活化形式就会产生。
• Topical compostions for lowering intraocular pressure
  申请人：ALCON LABORATORIES, INC.

  公开号：EP0081924B1

  公开（公告）日：1986-02-19
• 2-(Trisubstituted phenylimino)-imidazolines
  申请人：ALCON LABORATORIES, INC.

  公开号：EP0081923B1

  公开（公告）日：1987-01-21